Efaproxiral (sodium)
Efaproxiral sodium (RSR13 sodium) is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy. in vitro: Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Efaproxiral can enhance the oxygenation of hypoxic tumours and function as a radiation sensitiser, increasing the effectiveness of RT.
Product Specifications
CAS Number
170787-99-2
Product Name Alternative
RSR13 (sodium)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Efaproxiral-sodium.html
Purity
99.72
Solubility
DMSO : 175 mg/mL (ultrasonic) |H2O : ≥ 33.33 mg/mL
Smiles
CC(C)(OC1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1)C(O[Na])=O
Molecular Formula
C20H22NNaO4
Molecular Weight
363.38
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD8b, Mouse (H35-17.2), CF488A conjugate, 0.1mg/mL
HSP27 (Heat Shock Protein 27) (rHSPB1/774), CF647 conjugate, 0.1mg/mL
Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) (rGPC3/863), CF594 conjugate, 0.1mg/mL
SOX10 (Melanoma Marker) (rSOX10/1074), CF640R conjugate, 0.1mg/mL
